Web19 Jan 2024 · Serum Institute of India is engaged in manufacturing and exporting life-saving immunobiologicals and has established itself as one of the world's largest producers of measles and diphtheria, tetanus and pertussis vaccines. Its products have been used in 145 countries worldwide. The institute has a history of philanthropy. Visit the Serum ... Web15 Feb 2024 · Funding. Serum Institute of India Pvt. Ltd. has made 5 investments. Their most recent investment was on Feb 15, 2024, when Codagenix raised $25M. Serum Institute of India Pvt. Ltd. has had 2 exits. Serum Institute of India Pvt. Ltd. 's most notable exits include Oxford BioMedica and Visterra.
Working at Serum Institute of India Glassdoor
WebGreetings connections! I am absolutely ecstatic to share that i have completed my internship at serum institute of India pvt.Ltd successfully. In the duration of my internship i learned various ... Web8 Nov 2024 · Serum Institute of India manufacturers of Vaccines & immuno-biologicals that include Tetanus Toxoid, Diphtheria, Measles, Mumps, Rubella and Hepatitis... read more HQ - Pune, India Pharma 1k-5k Employees (India) Biotechnology Write a Review Compare About Reviews 261 Salaries 1.6k Interviews 15 Jobs 2 Benefits 117 Photos Q&A 2 Filter reviews by body of a lion
Serum Institute of India Pvt. Ltd. - CrunchBase
Web4 Jun 2024 · Adar Poonawalla, Chief Executive Officer, SII, said: “Serum Institute of India is delighted to partner with AstraZeneca in bringing this vaccine to India as well as low and middle-income countries. Over the past 50 years SII has built significant capability in vaccine manufacturing and supply globally. WebQualification : Science Graduate. Experience : 5 - 7 Years. Key Skills : Hands-on experience in Receipt and dispensing function of Raw material and packing material. Exposure to cGMP … Web8 Sep 2024 · 8th September 2024. Oxford spinout Spybiotech partners Serum Institute of India on new potential vaccine for COVID-19. SpyBiotech, a company with a novel vaccine platform to target infectious diseases, cancer and chronic diseases, today announces that its partner the Serum Institute of India (SIIPL) has dosed the first subjects in a Phase I/II … glen erin and thomas